The turnout at last week's Food and Drug Administration hearing was unusually large, with many a gleaming pate to be seen in the crowd. The subject of discussion: minoxidil (brand name: Rogaine), the Upjohn Co. preparation that has given new hope to the balding and new vigor to the company's stock. Originally marketed as a treatment for hypertension, minoxidil, in liquid form, was found by 48% of the men in an Upjohn study to produce "moderate-to- dense" hair growth if applied twice daily. Dermatologist Robert Stern, who headed an FDA advisory panel reviewing the drug, finds this a bit misleading. "Under...
To continue reading:
or
Log-In
